Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study
- Ensysce Biosciences (NASDAQ:ENSC) has enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study.
- The trial is evaluating PF614-MPAR, an opioid candidate incorporating MPAR® technology designed to provide overdose protection.
- The study is supported by the National Institute on Drug Abuse and follows FDA Breakthrough Therapy designation for the program.
Ensysce Biosciences (NASDAQ:ENSC) announced that the first patient has been enrolled in the final stage of the PF614-MPAR-102 clinical study.
The trial is evaluating PF614-MPAR, the company’s lead opioid candidate featuring MPAR® overdose-protection technology.
This advancement marks a significant step in the clinical development of PF614-MPAR for the treatment of severe pain while aiming to reduce risks associated with traditional opioids.
The study is supported by the National Institute on Drug Abuse.
PF614-MPAR has previously received Breakthrough Therapy designation from the FDA.
Ensysce Biosciences is focused on developing next-generation opioid analgesics with built-in abuse-deterrent and overdose-protection features.
The company continues to advance its pipeline of innovative pain management therapies targeting significant unmet needs in the treatment of severe pain.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
